

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**SUCCESSFUL INCLUSION OF SIX PRODUCTS OF THE GROUP INTO
JIANGSU MEDICAL INSURANCE CATALOGUE**

This announcement is made by the board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis.

The Board is pleased to announce that, according to the notice in relation to Jiangsu Medicine Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2018 Edition) (the “Jiangsu Medical Insurance Catalogue”) published by Jiangsu Provincial Department of Human Resources and Social Security, another six products of the Group in total were successfully listed on the Jiangsu Medical Insurance Catalogue, with details as follows:

No.	Medicine	Group company	Main functions/Indications
Western medicines			
1	Carbohydrate and Electrolyte Injection (“Xinhaineng”)	Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.	As a new fourth-generation carbohydrate and electrolyte product, it can fully supplement various substances required by our body and maintain balance and stability of body fluids, which is the preferred infusion for perioperative liquid treatment. It can also be used as preferred supplements of energy and electrolytes for patients who are prohibited to eat or can only take in fluids or semi-fluids.

No.	Medicine	Group company	Main functions/Indications
2	Pronase Granules (“Deyou”)	Beijing Tide Pharmaceutical Co. Ltd.	As a preparative medication before gastroscopy test, it is the only gastric mucus dissolving agent in China; in clinical use, it can significantly improve visibility of gastroscopy and the image quality, which significantly increases the detection rate of lesions of early gastric cancer.
3	Oral Palonosetron (“Ruoshan”)	Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.	As a second-generation 5-HT ₃ receptor antagonist, it is used for preventing nausea and vomiting caused by moderate and high-level emetic chemotherapy; it is more convenient and safer for clinical use and can achieve better patient compliance, which greatly improves the quality of life of patients.
4	Oral Lactitol Powder (“Tianqingkang xin”)	Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.	This disaccharide derivative comprising sorbitol and galactose is for treatment of hepatic encephalopathy and chronic constipation; its efficacy is good, incidence of adverse reactions is low and patient compliance is good.
Proprietary Chinese medicines			
5	Guibai Soft Capsule (“Qingbishu”)	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.	For treatment of chronic non-bacterial prostatitis blood stasis and dampness fever, it is the only proprietary Chinese medicine to relieve prostate pain; with characteristics of easy taking, mild adverse reactions and rapid curative effect.
6	Anluotong Soft Capsule	Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd.	For dysmenorrhea, improving blood circulation, pain relief, bruises, rheumatoid arthritis and other joint pain.

The above products contributed more than RMB560 million in aggregate in sales revenue of the Group for the year ended 31 December 2017. Jiangsu Province is traditionally a major province engaged in the pharmaceutical industry, and its pharmaceutical output value plays a decisive role in the national pharmaceutical industry in China. The inclusion of additional products of the Group into the Jiangsu Medical Insurance Catalogue will further facilitate the application of these products in the hospitals within Jiangsu Province and meet more clinical needs that are currently not fulfilled, which will not only

help boost the sales and market distribution of related products, but also lay a solid foundation for the Group's products to be listed on medical insurance catalogue of other provinces, while providing more patients with high quality and affordable medicines.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairlady

Hong Kong, 26 April 2018

As at the date of this announcement, the Board of the Company comprises seven Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.